BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Sildenafil (Revatio® and Viagra®): should not be used to treat intrauterine growth restriction

Active substance: sildenafil

The STRIDER clinical trial, which was studying sildenafil for treating intrauterine growth restriction (IUGR), has been prematurely discontinued due to a higher incidence of persistent pulmonary hypertension of the newborn (PPHN) and overall neonatal death in the sildenafil arm of the study. Sildenafil is not approved for IUGR and should not be used for treating IUGR. Sildenafil should only be used in accordance with the current product information.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 165KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK